MDs
MDs
This section is for doctors who are considering the selection of PRRT to treat one of their patients.
Considering PRRT for a Patient: What a physician should look for
Progressive, somatostatin receptor positive neuroendocrine tumor patients (non-resectable disease) with the following characteristics:
* A fundamental prerequisite is that high somatostatin receptor expression has been proven before PRRT by OctreoScan or (preferable) by Ga-68 DOTATOC PET/CT.
* Renal function and blood counts should be in the normal range.
* Small bowel tumors (midgut), progressive under octreotide (Sandostatin, Somatuline) therapy - 1st line before chemotherapy
* Small bowel tumors (midgut) with persistent, severe clinical symptoms (diarrhea, flushing)